Updated Jul 16, 2026 · Last SEC filing 2026-07-09
Syndax Pharmaceuticals Inc (SNDX) has filed 4 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-09. 4 Form 8-K material event filings were reported by SNDX in the last 90 days. 5 Form 144 notices of proposed sale were filed for SNDX stock. InsiderAlpha tracks every SNDX SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0001395937 |
|---|
| Form 4 filings (90d) | 4 |
|---|---|
| Form 8-K filings (90d) | 4 |
| Form 144 notices (90d) | 5 |
| Latest Form 4 filing | 2026-07-09 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Metzger Michael A | Chief Executive Officer | M — Option exercise | 32.4K | $6.38 | $207K | SEC | |
| Metzger Michael A | Chief Executive Officer | S — Open-market sale | 32.4K | $24.24 | $785K | SEC | |
| Botwood Nicholas A.J. | Head of R&D, CMO | S — Open-market sale | 31.2K | $18.14 | $567K | SEC | |
| Botwood Nicholas A.J. | Head of R&D, CMO | M — Option exercise | 31.2K | $13.82 | $432K | SEC | |
| Botwood Nicholas A.J. | Head of R&D, CMO | M — Option exercise | 22.5K | $13.82 | $311K | SEC | |
| Botwood Nicholas A.J. | Head of R&D, CMO | S — Open-market sale | 34.3K | $18.00 | $617K | SEC | |
| Goldan Keith A. | Chief Financial Officer | S — Open-market sale | 1.2K | $18.99 | $22K | SEC | |
| Metzger Michael A | Chief Executive Officer | S — Open-market sale | 6.8K | $18.99 | $130K | SEC | |
| Metzger Michael A | Chief Executive Officer | S — Open-market sale | 17.2K | $21.03 | $361K | SEC | |
| Goldan Keith A. | Chief Financial Officer | S — Open-market sale | 3.4K | $21.03 | $72K | SEC | |
| Metzger Michael A | Chief Executive Officer | S — Open-market sale | 7.4K | $20.62 | $153K | SEC | |
| Goldan Keith A. | Chief Financial Officer | S — Open-market sale | 2.1K | $20.62 | $43K | SEC | |
| Katkin Keith | Insider | A — Grant or award | 24.0K | $0.00 | — | SEC | |
| Rizo Aleksandra | Insider | A — Grant or award | 24.0K | $0.00 | — | SEC | |
| Botwood Nicholas A.J. | Head of R&D, CMO | A — Grant or award | 24.0K | $0.00 | — | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Syndax Pharmaceuticals Inc (SNDX). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Botwood Nicholas A.J. | 6 | $1.93M |
| Metzger Michael A | 4 | $1.12M |
| Goldan Keith A. | 1 | $22K |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in SNDX insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live SNDX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.